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University of Padova, Via Giustiniani 2, 35126 Padova, ItalySee Article, pages 279–287It is clearly established that patients with cirrhosis
who respond to 1–3 month beta-blocker treatment with
a decrease in their hepatic venous pressure gradient
(HVPG) to 612 mmHg or ofP20% of the baseline val-
ues are protected from the risk of variceal bleeding,
while such risk pertains almost exclusively to patients
who do not meet these hemodynamic response criteria
[1,2]. This holds true both in the setting of primary pro-
phylaxis and that of prevention of rebleeding. In addi-
tion, hemodynamic criteria represent the only
validated prognostic indicator of clinical eﬀectiveness
of treatment with beta-blockers. A recent meta-analysis
showed that the risk of bleeding in hemodynamic ‘‘good
responders” is markedly lower than that of ‘‘poor
responders” [3]. However, concerns have been raised in
relation to the feasibility, the clinical appropriateness,
the risks and the costs of repeat HVPG measurement
[4], which is an invasive procedure and needs to be per-
formed twice within a 1–3 month period in order to
deﬁne response. These problems have long been known
to investigators involved in the study of portal hyperten-
sion, and eﬀorts were devoted to try to overcome them.
For instance, the potential predictive role of the
response to the ﬁrst dose of beta-blockers, administered
under HVPG measurement, was explored but subse-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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changes appeared markedly diﬀerent from the chronic
ones in many patients [5–7], possibly in relation to the
hypotensive eﬀect of the ﬁrst dose, and the absence of
those systemic and regional hemodynamic adjustments
which only occur during long-term treatment [7].
In this issue of the Journal, La Mura and colleagues
[8] challenge these consolidated general lines, reporting a
cohort study of patients with cirrhosis and portal hyper-
tension, in whom the hemodynamic response to the ﬁrst
dose of beta-blocker, administered under HVPG mea-
surement, was highly predictive of the clinical eﬃcacy
of long-term treatment, and was even more predictive
than the response to chronic beta-blocker administra-
tion. Furthermore, they observed that the best threshold
discriminating good from poor responders on the basis
of the acute beta-blocker challenge was a 12% decrease
in HVPG instead of the widely accepted 20% value
emerging from studies of chronic response. The predic-
tive value of the acute challenge was particularly evident
in the scenario of the prevention of rebleeding, where the
number of ‘‘events” was higher. The eﬀect could be
detected also in the setting of primary prophylaxis,
although it did not reach statistical signiﬁcance.
Based on these data, should we reconsider our previ-
ously accepted guidelines, and modify our clinical
practices to introduce the response to the ﬁrst dose of
beta-blockers as an indicator of clinical eﬃcacy?
Before jumping to conclusions, it is probably appro-
priate to consider these data and their implications in
further detail. Firstly, the choice of a 12% threshold
value was a data-driven, post-hoc choice, as the authorsPublished by Elsevier B.V. All rights reserved.
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point had been already proposed in 1991 [9], but was
subsequently replaced by the 20% threshold, which
gained strength from several reports [3], and became
an almost ‘‘magic number”. It is uncertain whether the
newly proposed 12% threshold will prove valid once uti-
lized as a predeﬁned criterion.
In addition, the prognostic value of the response to
the acute challenge in this series was much weaker than
that reported in previous chronic studies. Indeed, the
risk of bleeding in poor responders to acute challenge
was approximately double compared to that of good
responders both in the context of the prevention of
rebleeding, and in that of primary prophylaxis. These
values are very diﬀerent from those reported in a
meta-analysis, based on all available literature, pro-
duced by D’Amico and colleagues [3], who reported
an approximately 6-fold higher risk for poor responders
in prevention of rebleeding, and a 7-fold higher risk in
primary prophylaxis, compared to the good responders,
as expressed by the pooled Odds Ratios. Since in the
present series the discriminating ability of the chronic
eﬀect was reported to be lower than that of the acute
challenge, as inferred from the larger misclassiﬁcation
rate, we have to conclude that this series is quite diﬀer-
ent from those already published, especially in relation
to the poor discriminatory ability of the chronic eﬀect.
It is, therefore, conceivable that the higher predictive
value of the acute challenge compared to the chronic
eﬀect may be due to some peculiar features of the patient
population, who turned out to be unﬁt for the prediction
of the clinical outcome based on the chronic eﬀect.
Furthermore, the clinical relevance of a classiﬁcation
error varies according to the occurrence of a false-posi-
tive or false-negative result. Indeed, it is expected that
only a limited number of the poor responders will
undergo a variceal bleeding, and, at least within the con-
text of primary prophylaxis, the majority will not bleed
during follow-up; conversely, it is very important from a
clinical point of view to minimize the number of the
patients classiﬁed as good responders who actually
bleed. In the latter situation, the classiﬁcation error
bears relevant clinical consequences, as the use of an
ineﬀective treatment, which is believed to be eﬀective,
prevents us from using an alternative treatment which
may be more eﬀective [10,11]. From the present report
it appears that most classiﬁcation errors are of the ﬁrst
type (poor responders who do not bleed during follow-
up), even though exact values are not provided. If the
diﬀerence in the misclassiﬁcation rate between acute
challenge and chronic treatment is due, at least to an
extent, to the occurrence of bleeding in individuals clas-
siﬁed as good responders to chronic treatment, this dif-
ference would be of importance.
Finally the pathophysiology of the issue needs to be
considered. While it follows from the available knowl-edge that a stable decrease in portal pressure is important
in lowering the risk of bleeding in these patients, together
with all the other complications of portal hypertension
[12], and that keeping a good hemodynamic response
during the course of treatment is also a positive prognos-
tic factor [13], the mechanisms underlying the relation-
ship between the response to the ﬁrst dose, which also
in this series was shown to be very frequently diﬀerent
from that during chronic treatment, and the long-term
clinical outcome are only partially understood.
For all these reasons, the data presented in the study
by La Mura and colleagues need external validation,
and many researchers involved in this area of research
may consider the appropriateness of performing such a
validation study. Meanwhile, I have re-analyzed a small
series from our study group, in which patients were eval-
uated both after acute challenge and after chronic treat-
ment with beta-blockers [7]. In this study, patients
classiﬁed as poor responders to chronic treatment were
switched to a combined treatment with beta-blockers
plus nitrates, while good responders were kept on
beta-blockers. In the 11 patients good responders to
chronic treatment six of whom were also good respond-
ers to the acute challenge (the remaining ﬁve were poor
responders to the acute challenge) the clinical outcome
in terms of variceal bleeding was evaluated [7]. Having
reclassiﬁed these patients on the basis of the 12% thresh-
old for a good response to the acute challenge, six were
qualiﬁed as acute good responders and ﬁve as acute
poor responders. Overall, there was a single patients
who bled during follow-up in the group of the 11
patients, and this individual was an acute good respond-
ers. In contrast, none of the patients belonging to the
group of the acute poor responders underwent variceal
bleeding. Thus this small series would not support the
hypothesis that the response to the acute challenge is a
better predictor of variceal bleeding. It would have also
been interesting to assess the clinical outcome of patients
classiﬁed as poor responders to chronic treatment, but
these were switched to combined treatment, and we do
not know what their outcome would have been had they
been treated with beta-blockers only.
In conclusion, while it seems early days for the imple-
mentation of the acute challenge as a predictor of out-
come, the very fact that these new data do not fully ﬁt
the currently accepted model for the relationship
between hemodynamic eﬀects and clinical outcome
may open new lines of research.
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